Aug 12, 2026 04:05PM
May 18, 2026 10:27AM
May 12, 2026 04:05PM
May 7, 2026 08:05AM
May 7, 2026 08:05AM
Mar 16, 2026 04:05PM
Mar 12, 2026 08:05AM Atara Biotherapeutics schedules FDA meeting on tabelecleucel application
Mar 12, 2026 08:05AM
Mar 3, 2026 08:06AM
Mar 3, 2026 08:05AM
Feb 23, 2026 08:00AM
Feb 23, 2026 08:00AM
Jan 12, 2026 08:05AM
Jan 12, 2026 08:04AM FDA rejects Atara Biotherapeutics' EBVALLO drug application
Jan 12, 2026 08:00AM
Jan 2, 2026 04:06PM
Nov 21, 2025 06:34AM
Nov 12, 2025 09:00AM
Nov 3, 2025 09:04AM
Nov 3, 2025 09:00AM
Sep 3, 2025 06:00PM Atara Biotherapeutics names Greg Ciongoli as board chair
Sep 3, 2025 06:00PM
Aug 18, 2025 06:25AM
Aug 11, 2025 04:01PM
Jul 24, 2025 08:57AM
Jul 24, 2025 08:00AM
Jul 24, 2025 08:00AM
Jul 15, 2025 08:00AM Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
Jul 14, 2025 08:01AM
Jul 14, 2025 08:00AM
May 28, 2025 08:00AM
May 15, 2025 08:35AM
May 5, 2025 05:06PM
Mar 7, 2025 04:01PM
Jan 28, 2025 06:41AM H.C. Wainwright Reiterates Neutral Rating on Atara Biotherapeutics (ATRA)
Jan 21, 2025 03:45PM
Jan 21, 2025 07:32AM
Jan 21, 2025 07:30AM
Jan 17, 2025 06:31AM
Jan 16, 2025 08:56AM
Jan 16, 2025 08:35AM
Jan 16, 2025 08:30AM Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
Nov 12, 2024 04:01PM
Aug 12, 2024 05:00PM
Jul 17, 2024 09:01AM
Jul 17, 2024 09:00AM
Jun 21, 2024 04:01PM
May 20, 2024 09:25AM
May 20, 2024 09:25AM Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Mar 28, 2024 08:30AM

329,629 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All